Targeting Estrogen Receptor Beta in a Phase 2 Study of High-Dose Estradiol in Metastatic Triple-Negative Breast Cancer: A Wisconsin Oncology Network Study

Clinical Breast Cancer - United States
doi 10.1016/j.clbc.2016.03.005
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Estrogen Receptor-Beta Is a Potential Target for Triple Negative Breast Cancer Treatment

Oncotarget
Oncology
2018English

Phase II and Biomarker Study of Cabozantinib in Metastatic Triple‐Negative Breast Cancer Patients

Oncologist
Cancer ResearchMedicineOncology
2017English

Phase II Study of Pembrolizumab and Capecitabine for Triple Negative and Hormone Receptor-Positive, HER2−negative Endocrine-Refractory Metastatic Breast Cancer

Journal for ImmunoTherapy of Cancer
OncologyMolecular MedicinePharmacologyCancer ResearchAllergyImmunology
2020English

A Multigene Predictor of Metastatic Outcome in Early Stage Hormone Receptor-Negative and Triple-Negative Breast Cancer

Breast Cancer Research
Cancer ResearchOncology
2010English

Development of a Vaccine Targeting Triple-Negative Breast Cancer

2013English

Phase II Study of Dehydroepiandrosterone in Androgen Receptor‐Positive Metastatic Breast Cancer

Oncologist
Cancer ResearchMedicineOncology
2018English

Dicer Expression in Estrogen Receptor–positive Versus Triple-Negative Breast Cancer: An Antibody Comparison

Human Pathology
Forensic MedicinePathology
2016English

Estrogen Receptor-Negative Breast Cancer: New Insights Into Subclassification and Targeting

Clinical Cancer Research
Cancer ResearchOncology
2009English

Estrogen Receptor Beta Participate in the Regulation of Metabolizm of Extracellular Matrix in Estrogen Alpha Negative Breast Cancer.

Folia Histochemica et Cytobiologica
MedicineForensic MedicinePathologyHistology
2010English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy